Compare stocks

Evaluate stocks side by side, to find the best fit for your investment goals.
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.
View stock
VS
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
View stock

Stock highlights

Stock comparison highlights
Stock name
Armata PharmaceuticalsEli Lilly
Last price
$3.81$1,162.08
Currency
USD
USD
$136M$1T
-38.37
-$5.27$29.79
1.350.50
0$6.69
00.61%
Sector
HealthHealth
Employees
6150,000
Ticker
$ARMP$LLY
Primary listing
AMEXNYSE

Performance

CumulativeRolling yearsLump sum investment

Invest in $ARMP or $LLY on Lightyear

Save on broker fees and invest in 6000+ stocks and funds. When you invest, your capital is at risk.